Clinical Trial

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Name: A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations — clinical trial record (NCT07629960)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.

Trial Details

NCT Number	NCT07629960
Lead Sponsor	Blueprint Medicines Corporation Collaborators: Sanofi
Conditions	Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Enrollment	265 participants
Start Date	2026-06-04
Primary Completion	2029-09 (estimated)
Study Completion	2031-07 (estimated)
Updated on ClinicalTrials.gov	2026-08-10